Trial Profile
A Multicenter, Randomized, Double-blind, Active-controlled Phase 2b Trial [Part of EU-funded UNISEC Project] to Assess the Immunogenicity & Safety of a BiondVax's Influenza Vaccine (M-001) Followed by H5N1 Vaccine in Healthy Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors BiondVax Pharmaceuticals; Scinai Immunotherapeutics
- 12 Apr 2018 According to a BiondVax Pharmaceuticals media release, results of this phase IIb trial will be presented at the Universal Influenza Vaccines 2018 Conference.
- 14 Aug 2017 Status changed from active, no longer recruiting to completed, according to BiondVax Pharmaceuticals media release.
- 20 Jul 2017 Results published in a BiondVax Pharmaceuticals Media Release.